Biomarkers in NSCLC

Welcome to the Biomarkers in NSCLC Resource Center! Here you will find updated information, education, and other resources from the field of non-small cell lung cancer. We're excited to provide this offering to you and your colleagues. Take a look around, and send us your feedback to editor@advancedpractitioner.com

Rasheda Persinger, NP-C, Medical Oncology Lead Nurse Practitioner, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital

Biomarkers in NSCLC Resource Center

Interview With Charita Marthone, PharmD, BCOP: Pathophysiology of Biomarker Targets

KRAS G12C Biomarker Testing & Analysis

CAP/IASLC/AMP Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices

Next-generation Sequencing-based Detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her-2 and TP53 Mutations in Patients With Non-small Cell Lung Cancer

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Non-Small Cell Lung Cancer

Translational Lung Cancer Research

Neoadjuvant Treatment of Stage IIIA-N2 in EGFR-Mutant/ALK-Rearranged Non–Small Cell Lung Cancer

Translational Lung Cancer Research

Emerging Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors in Operable Non–Small Cell Lung Cancer

European Journal of Cancer

COVID-19 in Lung Cancer Patients Receiving ALK/ROS1 Inhibitors

Journal of Clinical Oncology

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Lung Cancer

Biomarker Testing in Non-Small Cell Lung Cancer in Routine Care: Analysis of the First 3,717 Patients in the German Prospective, Observational, Nation-Wide CRISP Registry (AIO-TRK-0315)

Journal of Thoracic Oncology

Biomarker Discovery and Validation: Statistical Considerations

Cancer Discovery

Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers From Admixed Latin American Populations

JCO Precision Oncology

Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer

The Lancet Oncology

Pembrolizumab for Management of Patients With NSCLC and Brain Metastases: Long-Term Results and Biomarker Analysis From a Non-Randomised, Open-Label, Phase 2 Trial

Journal of Clinical Oncology

Cardiac Safety of Osimertinib: A Review of Data

Fast Facts #2: Pathways and Approved Targeted Therapies: An Overview